Notice of Class Action Lawsuit for GeneDx Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while significant issues with Fabric's viability negatively impacted GeneDx's overall operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in class actions to ensure optimal representation and support during litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 55.420
Low
155.00
Averages
171.43
High
200.00
Current: 55.420
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit for GeneDx Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while significant issues with Fabric's viability negatively impacted GeneDx's overall operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in class actions to ensure optimal representation and support during litigation.
See More
GeneDx CFO Sells Shares for Tax Obligations
- Sale Overview: GeneDx CFO Kevin Feeley sold 3,729 shares of Class A common stock on June 16, 2026, for a total transaction value of $226,596.87, representing 8.54% of his direct holdings, reducing his position from 43,683 to 39,954 shares.
- Option Exercise Context: The transaction stemmed from the exercise of 7,197 options, with the shares sold directly and no indirect or third-party involvement, indicating that the sale was almost entirely administrative in nature.
- Tax Planning Mechanism: According to the SEC Form 4 filing, Feeley's sale was to cover tax withholding obligations related to the vesting and settlement of restricted stock units, executed through a standard
See More
GeneDx CFO Sells Shares to Meet Tax Obligations
- Transaction Overview: GeneDx CFO Kevin Feeley sold 3,729 shares of Class A Common Stock for approximately $227,000 on June 16, 2026, following the exercise of 7,197 options, indicating routine financial management by company executives.
- Ownership Analysis: Post-transaction, Feeley retains 39,954 Class A shares valued at around $2.4 million, and while the sale represented 8.54% of his direct holdings, it did not significantly alter his overall equity structure.
- Company Financial Performance: With a market capitalization of $1.65 billion, GeneDx's stock has fallen 27% over the past year; despite a 17% year-over-year revenue increase to $102.3 million in Q1, the company lowered its full-year revenue guidance to a maximum of $490 million, reflecting challenges in the market environment.
- Future Outlook: Despite short-term challenges, CEO Katherine Stueland expressed unwavering confidence in the company's long-term profitable growth, and the appointment of a new president may provide fresh momentum for a turnaround, highlighting GeneDx's ongoing competitiveness in personalized medicine.
See More
GeneDx Holdings Faces Class Action for Securities Fraud
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a class action lawsuit for securities fraud, alleging significant misstatements during the acquisition of Fabric Genomics from April 16, 2025, to May 4, 2026, which has undermined investor confidence.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aimed at expanding its market through AI-driven genomic interpretation; however, the lawsuit claims serious viability issues with the acquisition misled stakeholders about the company's prospects.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, revealing a $31.3 million impairment loss related to Fabric, which caused its stock price to plummet by over 49% following the announcement.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by August 3, 2026, with KTMC offering free case evaluations, emphasizing that their rights to recovery remain intact regardless of their participation as lead plaintiffs.
See More
GeneDx Faces Securities Class Action After 49% Stock Drop
- Stock Price Plunge: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, which directly undermined investor confidence and could trigger broader sell-offs.
- Class Action Lawsuit: Hagens Berman has initiated a securities class action against GeneDx, representing investors who purchased shares between April 16, 2025, and May 4, 2026, alleging violations of federal securities laws that could lead to increased legal liabilities.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 compared to the previous year, with the Fabric Genomics unit missing revenue expectations by $2.5 million, resulting in $31.2 million in impairment charges that severely impacted financial health.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than prior expectations, indicating a dramatic shift in the company's growth narrative that may affect future investor confidence.
See More
Class Action Lawsuit Announced for GeneDx Holdings Corp.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April 16, 2025, and May 4, 2026, indicating potential losses due to false statements made by the company.
- Compensation Structure: Investors joining the lawsuit will not incur any out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers for affected investors and encouraging broader participation.
- Allegations of Misrepresentation: The lawsuit alleges that GeneDx knowingly or recklessly concealed significant issues regarding Fabric's viability post-acquisition, leading investors to misunderstand the company's financial health and impacting their investment decisions.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its capability and experience in handling similar cases.
See More
Notice of Class Action Lawsuit for GeneDx Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while significant issues with Fabric's viability negatively impacted GeneDx's overall operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, showcasing its expertise in this field.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in class actions to ensure optimal representation and support during litigation.
See More
GeneDx CFO Sells Shares for Tax Obligations
- Sale Overview: GeneDx CFO Kevin Feeley sold 3,729 shares of Class A common stock on June 16, 2026, for a total transaction value of $226,596.87, representing 8.54% of his direct holdings, reducing his position from 43,683 to 39,954 shares.
- Option Exercise Context: The transaction stemmed from the exercise of 7,197 options, with the shares sold directly and no indirect or third-party involvement, indicating that the sale was almost entirely administrative in nature.
- Tax Planning Mechanism: According to the SEC Form 4 filing, Feeley's sale was to cover tax withholding obligations related to the vesting and settlement of restricted stock units, executed through a standard
See More
GeneDx CFO Sells Shares to Meet Tax Obligations
- Transaction Overview: GeneDx CFO Kevin Feeley sold 3,729 shares of Class A Common Stock for approximately $227,000 on June 16, 2026, following the exercise of 7,197 options, indicating routine financial management by company executives.
- Ownership Analysis: Post-transaction, Feeley retains 39,954 Class A shares valued at around $2.4 million, and while the sale represented 8.54% of his direct holdings, it did not significantly alter his overall equity structure.
- Company Financial Performance: With a market capitalization of $1.65 billion, GeneDx's stock has fallen 27% over the past year; despite a 17% year-over-year revenue increase to $102.3 million in Q1, the company lowered its full-year revenue guidance to a maximum of $490 million, reflecting challenges in the market environment.
- Future Outlook: Despite short-term challenges, CEO Katherine Stueland expressed unwavering confidence in the company's long-term profitable growth, and the appointment of a new president may provide fresh momentum for a turnaround, highlighting GeneDx's ongoing competitiveness in personalized medicine.
See More
GeneDx Holdings Faces Class Action for Securities Fraud
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a class action lawsuit for securities fraud, alleging significant misstatements during the acquisition of Fabric Genomics from April 16, 2025, to May 4, 2026, which has undermined investor confidence.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aimed at expanding its market through AI-driven genomic interpretation; however, the lawsuit claims serious viability issues with the acquisition misled stakeholders about the company's prospects.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, revealing a $31.3 million impairment loss related to Fabric, which caused its stock price to plummet by over 49% following the announcement.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by August 3, 2026, with KTMC offering free case evaluations, emphasizing that their rights to recovery remain intact regardless of their participation as lead plaintiffs.
See More
GeneDx Faces Securities Class Action After 49% Stock Drop
- Stock Price Plunge: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, which directly undermined investor confidence and could trigger broader sell-offs.
- Class Action Lawsuit: Hagens Berman has initiated a securities class action against GeneDx, representing investors who purchased shares between April 16, 2025, and May 4, 2026, alleging violations of federal securities laws that could lead to increased legal liabilities.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 compared to the previous year, with the Fabric Genomics unit missing revenue expectations by $2.5 million, resulting in $31.2 million in impairment charges that severely impacted financial health.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than prior expectations, indicating a dramatic shift in the company's growth narrative that may affect future investor confidence.
See More
Class Action Lawsuit Announced for GeneDx Holdings Corp.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April 16, 2025, and May 4, 2026, indicating potential losses due to false statements made by the company.
- Compensation Structure: Investors joining the lawsuit will not incur any out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers for affected investors and encouraging broader participation.
- Allegations of Misrepresentation: The lawsuit alleges that GeneDx knowingly or recklessly concealed significant issues regarding Fabric's viability post-acquisition, leading investors to misunderstand the company's financial health and impacting their investment decisions.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its capability and experience in handling similar cases.
See More
